ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Autosomal recessive A20 zinc finger 7 mutation is associated with early-onset lupus-like disease.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA20 is an anti-inflammatory protein that suppresses nuclear factor-κB (NF-κB)-mediated inflammatory gene expression and inhibits cell death. Disruption of A20 function results in defective suppression of the NF-κB pathway, manifesting in diverse autoimmune and autoinflammatory conditions. While autosomal dominant A20 mutations have been identified to cause autoinflammatory disease, recessive A20 mutations causing disease have not been previously described.
methodsWe utilized whole exome sequencing to identify the variant of interest. In silico structural modeling as well as immunoprecipitation were used to ascertain A20's interaction with linear ubiquitin, coupled with flow cytometric analysis and western blotting to measure the expression of NF-κB activation markers. We quantified NF-κB pathway activity using NF-κB reporter assay.
resultsHere, we report a novel homozygous mutation in the A20 protein responsible for early-onset lupus-like disease starting at four years of age. We show that the A20 E781K variant, situated in the seventh zinc finger domain of A20, compromises the protein's ability to bind linear ubiquitin, resulting in a functional hypomorph with a reduced capacity to inhibit NF-κB activation and downstream gene expression in HEK293 cells.
conclusionOur findings characterize a critical mutation associated with early-onset lupus-like disease in its recessive form and continue to highlight the important role of A20 in maintaining immune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.